{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:32:38Z","timestamp":1744216358308},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00520-016-3391-z","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T04:09:05Z","timestamp":1472530145000},"page":"297-301","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["2016 Updated MASCC\/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential"],"prefix":"10.1007","volume":"25","author":[{"given":"Ian","family":"Olver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia N.","family":"Rittenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Clark-Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"3391_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris KG, Grunberg SM, et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109","journal-title":"J Clin Oncol"},{"key":"3391_CR2","doi-asserted-by":"crossref","unstructured":"Grunberg SM, Osaba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic emetogenicity\u2014an update. Support Care Cancer 13:80\u201384","DOI":"10.1007\/s00520-004-0718-y"},{"key":"3391_CR3","unstructured":"http:\/\/www.mascc.org\/antiemetic-guidelines Last accessed 27th Feb 2016"},{"issue":"2","key":"3391_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00063030-199912020-00004","volume":"12","author":"CM Perry","year":"1999","unstructured":"Perry CM, Wiseman LR (1999) Trastuzumab. BioDrugs 12(2):129\u2013135","journal-title":"BioDrugs"},{"key":"3391_CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10637-008-9152-1","volume":"27","author":"N Al-Dasooqi","year":"2009","unstructured":"Al-Dasooqi N, Boen JM, Gibson RJ, et al. (2009) Trastuzumab induces gastrointestinal side effects in HER2-overexpresssing breast cancer patients. Investig New Drugs 27:173\u2013178","journal-title":"Investig New Drugs"},{"key":"3391_CR6","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125514lbl.pdf Last accessed 27th February 2016"},{"key":"3391_CR7","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 372:2521\u20132532","journal-title":"New Engl J Med"},{"key":"3391_CR8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00520-006-0106-x","volume":"14","author":"LH Einhorn","year":"2006","unstructured":"Einhorn LH, Brames MJ (2006) Emetic potential of daily oral etoposide. Support Care Cancer 14:1262\u20131265","journal-title":"Support Care Cancer"},{"key":"3391_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00520-004-0703-5","volume":"13","author":"M Tonato","year":"2005","unstructured":"Tonato M, Clark-Snow RA, Osoba D, et al. (2005) Emesis induced by low or minimal emetogenic risk chemotherapy. Support Care Cancer 13:109\u2013111","journal-title":"Support Care Cancer"},{"key":"3391_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JOP.2011.000397","volume":"7","author":"E Basch","year":"2011","unstructured":"Basch E, Hesketh PJ, Kris MJ, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Practice 7:395\u2013398","journal-title":"J Oncol Practice"},{"key":"3391_CR11","unstructured":"https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf . Last accessed 17th Feb 2016"},{"key":"3391_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, et al. (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015","journal-title":"Br J Cancer"},{"key":"3391_CR13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2004.09.040","volume":"22","author":"Italian group for antiemetic research","year":"2004","unstructured":"Italian group for antiemetic research (2004) Randomised double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:752\u2013729","journal-title":"J Clin Oncol"},{"key":"3391_CR14","doi-asserted-by":"publisher","unstructured":"Costa AL, Abreu C, Pacheo TR et al (2015) Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumours. Biomed Res Int. Article ID 309601. doi: 10.1155\/2015\/309601","DOI":"10.1155\/2015\/309601"},{"key":"3391_CR15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00520-011-1278-6","volume":"20","author":"T Hayashi","year":"2010","unstructured":"Hayashi T, Ikesue H, Esaki T, et al. (2010) Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. Support Care Cancer 20:1805\u20131810","journal-title":"Support Care Cancer"},{"key":"3391_CR16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.7314\/APJCP.2013.14.1.469","volume":"14","author":"CH Keat","year":"2013","unstructured":"Keat CH, Phua G, Kassim MSA, et al. (2013) Can granisetron injection used as a primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy? Asia Pacific J Cancer Prev 14:469\u2013473","journal-title":"Asia Pacific J Cancer Prev"},{"key":"3391_CR17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00520-002-0427-3","volume":"11","author":"A Fabi","year":"2011","unstructured":"Fabi A, Barduagni M, Lauro S, et al. (2011) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156\u2013161","journal-title":"Support Care Cancer"},{"key":"3391_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","volume":"16","author":"A Molassiotis","year":"2008","unstructured":"Molassiotis A, Saunders MP, Valle J, et al. (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201\u2013208","journal-title":"Support Care Cancer"},{"key":"3391_CR19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla R, Lichinitser M, Van Der Vegt S, et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570\u20131577","journal-title":"Ann Oncol"},{"key":"3391_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124","journal-title":"Lancet Oncol"},{"key":"3391_CR21","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449","journal-title":"Ann Oncol"},{"key":"3391_CR22","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1185\/03007995.2011.596201","volume":"27","author":"L Schwartzberg","year":"2011","unstructured":"Schwartzberg L, Morrow G, Balu S, et al. (2011) Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin 27:1613\u20131622","journal-title":"Curr Med Res Opin"},{"key":"3391_CR23","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00520-012-1527-3","volume":"20","author":"PJ Hesketh","year":"2012","unstructured":"Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D (2012) Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Support Care Cancer 20:2633\u20132637","journal-title":"Support Care Cancer"},{"key":"3391_CR24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomised phase II trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"3391_CR25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1091\u20131090","journal-title":"Ann Oncol"},{"key":"3391_CR26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19:807\u2013813","journal-title":"Support Care Cancer"},{"key":"3391_CR27","first-page":"257","volume":"5","author":"RW D\u2019Acqusito","year":"1986","unstructured":"D\u2019Acqusito RW, Tyson LB, Gralla RJ, et al. (1986) The influence of chromic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3391_CR28","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/1097-0142(19850615)55:12<2766::AID-CNCR2820551207>3.0.CO;2-7","volume":"55","author":"GR Morrow","year":"1985","unstructured":"Morrow GR (1985) The effect of susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55:2766\u20132770","journal-title":"Cancer"},{"key":"3391_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/pon.804","volume":"14","author":"IN Olver","year":"2005","unstructured":"Olver IN, Taylor AE, Whitford H (2005) Relationships between patients\u2019 pre-treatment expectations of toxicities and post chemotherapy experiences. Psycho-Oncology 14:25\u201333","journal-title":"Psycho-Oncology"},{"key":"3391_CR30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, et al. (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986\u20131992","journal-title":"Ann Oncol"},{"key":"3391_CR31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00520-014-2372-3","volume":"23","author":"S Yu","year":"2014","unstructured":"Yu S, Burke TA, Chan A, et al. (2014) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy\u2014a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 23:273\u2013282","journal-title":"Support Care Cancer"},{"key":"3391_CR32","doi-asserted-by":"crossref","unstructured":"Olver I, von Dincklage J, Nicholson J, Shaw T (2016) Improving uptake of wiki-based guidelines with Qstream education. Med Educ 50:590\u2013591","DOI":"10.1111\/medu.13029"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3391-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:39:30Z","timestamp":1601051970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3391-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3391-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}